Acumen Pharmaceuticals Inc (ABOS) — Cash Flow-to-Debt Ratio
Acumen Pharmaceuticals Inc (ABOS) has a Cash Flow-to-Debt Ratio of -0.52x as of March 2026, meaning its operating cash flow of $-24.13 Million could theoretically repay -1% of its total liabilities ($46.15 Million) in one year. Explore Acumen Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Acumen Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Acumen Pharmaceuticals Inc across 7 annual periods. Also explore balance sheet size of Acumen Pharmaceuticals Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Acumen Pharmaceuticals Inc (2019–2025)
Year-by-year debt coverage analysis for Acumen Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Acumen Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-115.54 Million | $52.40 Million | ▼ -46.2% |
| 2024 | -1.51x | $-86.22 Million | $57.18 Million | ▼ -51.1% |
| 2023 | -1.00x | $-43.06 Million | $43.15 Million | ▲ +77.8% |
| 2022 | -4.50x | $-35.15 Million | $7.81 Million | ▼ -29.0% |
| 2021 | -3.49x | $-17.96 Million | $5.15 Million | ▼ -2851.9% |
| 2020 | -0.12x | $-7.45 Million | $63.02 Million | ▲ +67.5% |
| 2019 | -0.36x | $-6.82 Million | $18.74 Million | — |